MARKET

VSTM

VSTM

Verastem
NASDAQ
0.4000
+0.0050
+1.27%
After Hours: 0.4290 +0.029 +7.25% 19:39 12/07 EST
OPEN
0.3850
PREV CLOSE
0.3950
HIGH
0.4100
LOW
0.3850
VOLUME
498.02K
TURNOVER
0
52 WEEK HIGH
2.560
52 WEEK LOW
0.2895
MARKET CAP
84.04M
P/E (TTM)
-1.0121
1D
5D
1M
3M
1Y
5Y
Verastem Third Quarter 2022 Earnings: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021)
Verastem ( NASDAQ:VSTM ) Third Quarter 2022 Results Key Financial Results Net loss: US$18.1m (loss narrowed by 21% from...
Simply Wall St. · 11/08 13:22
Cigna To Rally 15%? Plus Needham Slashes PT On This Stock By 40%
Benzinga · 11/07 14:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 11/07 12:37
--HC Wainwright Adjusts Verastem's Price Target to $3 From $5, Keeps Buy Rating
--HC Wainwright Adjusts Verastem's Price Target to $3 From $5, Keeps Buy Rating
MT Newswires · 11/07 09:29
--RBC Trims Verastem's Price Target to $3 From $5, Keeps Outperform, Speculative Risk Rating
--RBC Trims Verastem's Price Target to $3 From $5, Keeps Outperform, Speculative Risk Rating
MT Newswires · 11/04 10:32
Verastem Oncology Q3 EPS $(0.08) Down From $(0.07) YoY
Benzinga · 11/03 21:31
Verastem GAAP EPS of -$0.09 beats by $0.03
Seekingalpha · 11/03 21:14
Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
Benzinga · 10/26 08:29
More
About VSTM
Verastem, Inc. is a biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. Its advanced product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. VS-6766 is an orally available small molecule RAF/MEK clamp. VS-6766 is a dual RAF/MEK clamp that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.

Webull offers kinds of Verastem Inc stock information, including NASDAQ:VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.